Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability
University of Texas Southwestern Medical Center
30 participants
Jun 30, 2023
OBSERVATIONAL
Conditions
Summary
Heart failure due to coronary artery disease represents a significant cause of mortality. The detection of patients eligible for bypass surgery is a pivotal concern. Nevertheless, the optimal approach for patient selection based on conventional imaging scans remains unclear. The proposed method (Hyperpolarized 13C MRI) has gained extensive use in evaluating in vivo metabolism. This method avoids ionizing radiation and provides critical insights into cardiac function. The feasibility study aims to investigate this method for patient selection before bypass surgery. This innovative imaging technique facilitates the identification of two simple molecules, bicarbonate and lactic acid, produced at high rates by normal heart metabolism. Both bicarbonate and lactate originate from the same precursor molecule, pyruvate. The data generated from this study holds the potential to refine diagnostic precision.
Eligibility
Inclusion Criteria1
- The eligibility criteria for this feasibility study are designed to select participants who will provide valuable insights into myocardial metabolism using HP-13C MRI in various contexts related to ischemic heart failure. These criteria aim to ensure that the study population is diverse and representative of the patient groups under investigation.
Exclusion Criteria17
- Age range: 20 to 80 years
- Sex: Random allocation
- Left ventricular ejection fraction (LVEF):
- Preoperative patients with LVEF \< 0.35
- Healthy subjects with LVEF \> 0.50
- Clinical history:
- Previous myocardial infarction (MI): Excluded for healthy subjects, included for preoperative patients.
- Diabetes mellitus: Excluded for all participants.
- Hypertension: Included for all participants
- Mean blood pressure: Systolic \< 140 mm Hg and Diastolic \< 90 mm Hg for all participants
- Mean heart rate: 78 beats/min for all participants
- Current smoker status: Included but will be reported.
- Medication use within 24 hours: Use will be reported.
- Coronary artery bypass surgery history: Excluded for healthy subjects, included for preoperative patients.
- Infarct type and location: Excluded for healthy subjects, included for preoperative patients with various Q-wave infarct types and locations.
- Number of diseased coronary vessels: Excluded for healthy subjects, included for preoperative patients with at least one diseased vessel.
- Additional medical history and clinical data: Variations in data availability are expected based on the practices of referring physicians and will be documented.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06047028